Mumps - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Mumps - Pipeline Review, H2 2015’, provides an overview of the Mumps’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Mumps, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mumps and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Mumps
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Mumps and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Mumps products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mumps pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mumps
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mumps pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mumps Overview 6
Therapeutics Development 7
Pipeline Products for Mumps - Overview 7
Pipeline Products for Mumps - Comparative Analysis 8
Mumps - Therapeutics under Development by Companies 9
Mumps - Therapeutics under Investigation by Universities/Institutes 10
Mumps - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Mumps - Products under Development by Companies 14
Mumps - Products under Investigation by Universities/Institutes 15
Mumps - Companies Involved in Therapeutics Development 16
Beijing Minhai Biotechnology Co., Ltd 16
Beijing Tiantan Biological Products Co., Ltd. 17
China National Pharmaceutical Group Corporation 18
GlaxoSmithKline Plc 19
Organic Vaccines 20
Prometheon Pharma, LLC 21
Sinovac Biotech Ltd. 22
Zydus Cadila Healthcare Limited 23
Mumps - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Cell Therapy for Measles, Mumps and Rubella - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
measles + mumps + rubella + varicella vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
measles + mumps + rubella + varicella vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
measles + mumps + rubella vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
measles + mumps + rubella vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
measles + mumps + rubella vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
measles [strain schwarz] + mumps [strain RIT 4385] + rubella [strain wistar RA 27/3] vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
mumps vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
mumps vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Mumps - Recent Pipeline Updates 39
Mumps - Dormant Projects 40
Mumps - Product Development Milestones 41
Featured News & Press Releases 41
Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44
List Of Tables
Number of Products under Development for Mumps, H2 2015 7
Number of Products under Development for Mumps - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Mumps - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 16
Mumps - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2015 17
Mumps - Pipeline by China National Pharmaceutical Group Corporation, H2 2015 18
Mumps - Pipeline by GlaxoSmithKline Plc, H2 2015 19
Mumps - Pipeline by Organic Vaccines, H2 2015 20
Mumps - Pipeline by Prometheon Pharma, LLC, H2 2015 21
Mumps - Pipeline by Sinovac Biotech Ltd., H2 2015 22
Mumps - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Assessment by Combination Products, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Mumps Therapeutics - Recent Pipeline Updates, H2 2015 39
Mumps - Dormant Projects, H2 2015 40
List Of Figures
Number of Products under Development for Mumps, H2 2015 7
Number of Products under Development for Mumps - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Combination Products, H2 2015 25
Number of Products by Top 10 Routes of Administration, H2 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26
Number of Products by Top 10 Molecule Types, H2 2015 28
Number of Products by Stage and Top 10 Molecule Types, H2 2015 28
